Trial
NCT02097121
OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Allergan
Collaborators
—
Condition
Urinary Incontinence
Intervention
BOTOX®
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-12-28